Finkelstein Thompson LLP Announces Investigation of Genoptix, Inc.
25 Janeiro 2011 - 9:29PM
Business Wire
Finkelstein Thompson LLP is investigating potential claims on
behalf of shareholders of Genoptix, Inc. (“Genoptix” or the
“Company”) (Nasdaq: GXDX) concerning the sale of the Company to
Novartis Finance Corp. for $25 in cash for every share of common
stock owned in a transaction valued at approximately $470 million.
The transaction is expected to close in the first half of 2011.
The investigation is focused on the potential unfairness of the
deal price to Genoptix shareholders, the process by which the Board
of Directors considered the transaction, and potential conflicts of
interests among Genoptix Board members. The stock was trading in
excess of $38 per share in May 2010, and according to Yahoo!
Finance at least one analyst has set a target price of $28 for
Genoptix’s shares.
If you are interested in discussing your rights as a Genoptix
shareholder, or have information relating to this investigation,
please contact Finkelstein Thompson's Washington, DC offices at
(877) 337-1050 or by email at contact@finkelsteinthompson.com.
Finkelstein Thompson LLP has spent over three decades delivering
outstanding representation to institutional and individual clients
in financial litigation, and has been appointed as lead or co-lead
counsel in dozens of shareholder class actions. Indeed, the firm
has served in leadership roles in cases that have recovered over $1
billion for investors and consumers.
To learn more about Finkelstein Thompson LLP, please visit our
web site at www.finkelsteinthompson.com. Attorney advertising.
Prior results do not guarantee similar outcomes.
Genoptix, Inc. (MM) (NASDAQ:GXDX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Genoptix, Inc. (MM) (NASDAQ:GXDX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
Notícias em tempo-real sobre Genoptix, Inc. (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Finkelstein Thompson LLP